SK42999A3 - Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof - Google Patents
Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof Download PDFInfo
- Publication number
- SK42999A3 SK42999A3 SK429-99A SK42999A SK42999A3 SK 42999 A3 SK42999 A3 SK 42999A3 SK 42999 A SK42999 A SK 42999A SK 42999 A3 SK42999 A3 SK 42999A3
- Authority
- SK
- Slovakia
- Prior art keywords
- composition
- aqueous liquid
- sodium
- liquid pharmaceutical
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2676596P | 1996-10-04 | 1996-10-04 | |
| GBGB9700541.7A GB9700541D0 (en) | 1997-01-13 | 1997-01-13 | Liquid alendronate formulation |
| US3600297P | 1997-01-22 | 1997-01-22 | |
| PCT/US1997/015740 WO1998014196A1 (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK42999A3 true SK42999A3 (en) | 2000-01-18 |
Family
ID=27268667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK429-99A SK42999A3 (en) | 1996-10-04 | 1997-10-02 | Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1007054A4 (ru) |
| JP (1) | JP2001501222A (ru) |
| CN (1) | CN1238691A (ru) |
| AU (1) | AU723357B2 (ru) |
| BG (1) | BG103306A (ru) |
| BR (1) | BR9712197A (ru) |
| CA (1) | CA2267370A1 (ru) |
| CZ (1) | CZ116999A3 (ru) |
| EA (1) | EA001213B1 (ru) |
| EE (1) | EE03669B1 (ru) |
| HU (1) | HUP0000125A3 (ru) |
| IL (1) | IL129127A0 (ru) |
| IS (1) | IS5012A (ru) |
| NO (1) | NO991569L (ru) |
| NZ (1) | NZ334836A (ru) |
| PL (1) | PL332496A1 (ru) |
| SK (1) | SK42999A3 (ru) |
| TR (1) | TR199900730T2 (ru) |
| WO (1) | WO1998014196A1 (ru) |
| YU (1) | YU17499A (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560490B2 (en) * | 2001-01-23 | 2009-07-14 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| JP2009508834A (ja) * | 2005-09-16 | 2009-03-05 | セラマイン リミテッド | ビスホスホネート製剤 |
| JP2010043119A (ja) * | 2009-10-16 | 2010-02-25 | Gador Sa | 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用 |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4206209A (en) * | 1978-11-02 | 1980-06-03 | Kracauer Paul | Sublingual aspirin tablet |
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
| US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
-
1997
- 1997-10-02 EP EP97945195A patent/EP1007054A4/en not_active Withdrawn
- 1997-10-02 WO PCT/US1997/015740 patent/WO1998014196A1/en not_active Application Discontinuation
- 1997-10-02 EA EA199900352A patent/EA001213B1/ru not_active IP Right Cessation
- 1997-10-02 HU HU0000125A patent/HUP0000125A3/hu unknown
- 1997-10-02 CZ CZ991169A patent/CZ116999A3/cs unknown
- 1997-10-02 TR TR1999/00730T patent/TR199900730T2/xx unknown
- 1997-10-02 JP JP10516541A patent/JP2001501222A/ja active Pending
- 1997-10-02 CA CA002267370A patent/CA2267370A1/en not_active Abandoned
- 1997-10-02 EE EEP199900113A patent/EE03669B1/xx not_active IP Right Cessation
- 1997-10-02 IL IL12912797A patent/IL129127A0/xx unknown
- 1997-10-02 CN CN97180165A patent/CN1238691A/zh active Pending
- 1997-10-02 BR BR9712197-5A patent/BR9712197A/pt unknown
- 1997-10-02 SK SK429-99A patent/SK42999A3/sk unknown
- 1997-10-02 AU AU46448/97A patent/AU723357B2/en not_active Ceased
- 1997-10-02 NZ NZ334836A patent/NZ334836A/xx unknown
- 1997-10-02 PL PL97332496A patent/PL332496A1/xx unknown
-
1999
- 1999-03-26 IS IS5012A patent/IS5012A/is unknown
- 1999-03-30 NO NO991569A patent/NO991569L/no not_active Application Discontinuation
- 1999-03-31 YU YU17499A patent/YU17499A/sr unknown
- 1999-04-02 BG BG103306A patent/BG103306A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR199900730T2 (xx) | 1999-07-21 |
| YU17499A (en) | 1999-11-22 |
| EA001213B1 (ru) | 2000-12-25 |
| EA199900352A1 (ru) | 1999-08-26 |
| EE03669B1 (et) | 2002-04-15 |
| CZ116999A3 (cs) | 1999-09-15 |
| IL129127A0 (en) | 2000-02-17 |
| IS5012A (is) | 1999-03-26 |
| BG103306A (en) | 2000-01-31 |
| AU723357B2 (en) | 2000-08-24 |
| EP1007054A4 (en) | 2000-07-19 |
| WO1998014196A1 (en) | 1998-04-09 |
| CA2267370A1 (en) | 1998-04-09 |
| NO991569L (no) | 1999-06-04 |
| PL332496A1 (en) | 1999-09-13 |
| BR9712197A (pt) | 1999-08-31 |
| EE9900113A (et) | 1999-10-15 |
| AU4644897A (en) | 1998-04-24 |
| EP1007054A1 (en) | 2000-06-14 |
| NZ334836A (en) | 2000-11-24 |
| HUP0000125A2 (hu) | 2000-06-28 |
| NO991569D0 (no) | 1999-03-30 |
| CN1238691A (zh) | 1999-12-15 |
| JP2001501222A (ja) | 2001-01-30 |
| HUP0000125A3 (en) | 2001-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0939624B1 (en) | Effervescent bisphosphonate formulation | |
| SK147796A3 (en) | Pharmaceutical formulation and its use | |
| EP0524579B1 (en) | Improved oral dosing formulations of dideoxy purine nucleosides | |
| CZ154997A3 (en) | Lyophilized preparation for oral administration | |
| PL181522B1 (en) | Ondansetrone containing oral compositions | |
| SK48395A3 (en) | Ranitidine chewable tablets | |
| ES2269014T3 (es) | Procedimiento para inhibir la resorcion osea. | |
| SK42999A3 (en) | Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof | |
| EP1067934B1 (en) | Oral liquid solution comprising the antidepressant mirtazapine | |
| US20040101563A1 (en) | Storage stable antihistaminic syrup formulations | |
| US7605148B2 (en) | Aqueous oral solution of bisphosphonic acid | |
| SK284847B6 (sk) | Perorálny vodný roztok obsahujúci ako aktívnu zložku 4-amino-5-chlór-2,3-dihydro-N-[1-(3-metoxypropyl)-4-piperidyl]-7- benzofuránkarboxamid a spôsob jeho prípravy | |
| ES2250211T3 (es) | Disolucion oral que contiene galantamina y un agente edulcorante. | |
| KR100752417B1 (ko) | 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물 | |
| WO2012150607A2 (en) | Oral liquid composition comprising divalproex sodium and process for preparing thereof | |
| KR20000048829A (ko) | 액체 알렌드로네이트 제형 | |
| JP6653931B2 (ja) | レベチラセタム含有ゲル経口医薬組成物 | |
| US6265449B1 (en) | Aqueous compositions comprising ranitidine and LCMT sucrose | |
| JP4195218B2 (ja) | 弱アルカリで安定化される薬剤を含む医薬用液剤 | |
| AU2007211965B2 (en) | Alendronate for use in the treatment of osteoporosis | |
| GR1009069B (el) | Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη | |
| GB2569615A (en) | An oral liquid pharmaceutical composition of lamotrigine` | |
| KR20160012921A (ko) | 블로난세린을 포함하는 구강 속붕해성 제제 |